NEWS
Bio-Path Holdings Initiates Development of Therapeutic Program for Treatment of Obesity
Bio-Path Holdings (NASDAQ:BPTH) has announced two significant developments:
1. Initiation of a therapeutic program to develop BP1001-A for treating obesity and related metabolic diseases, marking the first non-cancer application of their DNAbilize® technology.
2. Completion of enrollment in the third dosing cohort of the ongoing Phase 1/1b clinical trial evaluating BP1002 for refractory/relapsed acute myeloid leukemia (AML) patients, including venetoclax-resistant patients.
The company expects to begin preclinical studies for BP1001-A in Q4 2024, targeting insulin resistance. The rapid enrollment in the BP1002 trial highlights the urgent need for new treatment options in AML.
1. Initiation of a therapeutic program to develop BP1001-A for treating obesity and related metabolic diseases, marking the first non-cancer application of their DNAbilize® technology.
2. Completion of enrollment in the third dosing cohort of the ongoing Phase 1/1b clinical trial evaluating BP1002 for refractory/relapsed acute myeloid leukemia (AML) patients, including venetoclax-resistant patients.
The company expects to begin preclinical studies for BP1001-A in Q4 2024, targeting insulin resistance. The rapid enrollment in the BP1002 trial highlights the urgent need for new treatment options in AML.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
Spread kindness and love. Life is short. Don’t let greed eat you.
2377Followers
106Following
25KVisitors
Follow